Nathan Fuchs, Hallel Paraiso, Hannah Huang, I-Chen Ivorine Yu

Analysis of Cerebral Small Vessel Changes in an APOE4 Knock-In AD Mouse Model

Introduction

Analysis of cerebral small vessel changes in an apoe4 knock-in ad mouse model . Examine cerebral small vessel changes in an APOE4 Alzheimer's mouse model. Links APOE4 to decreased vessel diameter, increased plaque-vessel colocalization, and neuroinflammation, clarifying AD therapy side effects.

Abstract

Introduction:  Alzheimer’s disease (AD) is a complex neurodegenerative disorder and the leading cause of dementia worldwide.  Recently approved monoclonal antibody therapy has shown increased instances of amyloid-related imaging abnormalities (ARIA) in patients with the APOE4 allele compared to those with the APOE3 allele.  Although it is well established that AD adversely affects cerebral vasculature, the differential pathology between alleles is not fully understood.  This study aims to explore and quantify the changes of cerebral small vessels in a human APOE4 vs. APOE3 knock-in AD mouse model.  Methods:  Brains were collected from APOE3: APP-SAA and APOE4: APP-SAA mouse cohorts at 8 months.  Sectioning and staining were completed with immunofluorescence imaging of beta-amyloid (6E10), blood vessel (CD31), and microglia (Iba1) biomarkers.  Vessel density, diameter, signal intensity, and vessel-plaque colocalization were analyzed using NIH Fiji software, and t-tests were performed to compare averages between cohorts.  Results:  Two-tail t tests revealed a vessel density difference of -0.4956±0.4590% (t(8)=1.080;p=0.3118) and a CD31 intensity difference of -269881±169413au (t(8)=1.593;p=0.1498) showing no statistical significance.  Further testing showed a vessel diameter difference of -0.4043±0.02431 um (t(700)=16.63;p<0.0001).  Additionally, testing showed a plaque-vessel colocalization difference of 16.34±6.307% (t(51)=2.591;p=0.0124).  The qualitative assessment showed higher levels of microglial activation, a marker of neuroinflammation, in APOE4: APP-SAA brain samples.  Discussion:  The APOE4 allele is associated with adverse changes in cerebral small vessels in a controlled APOE3 vs. APOE4 APP-SAA model.  The observed pathology of increased neuroinflammation, decreased vessel diameter, and heightened amyloid-beta localization to cerebral small vessels may elucidate the mechanisms by which monoclonal antibody therapy targeting plaque removal results in increased pathological side effects related to vessel damage.  These findings warrant further studies on vascular changes responding to AD progression across ages and investigations into how this novel model may respond to monoclonal antibody therapy experiments. 

Review

This study addresses a highly relevant and timely topic in Alzheimer's disease research: the differential impact of APOE4 on cerebral small vessels. Given the increased incidence of amyloid-related imaging abnormalities (ARIA) in APOE4 carriers receiving novel monoclonal antibody therapies, understanding the allele-specific vascular pathology is critical. The authors' use of a human APOE4 vs. APOE3 knock-in APP-SAA AD mouse model provides a controlled and powerful platform to investigate these mechanisms, offering valuable insights into the underlying causes of vulnerability in APOE4 carriers. The methodology employed, involving immunofluorescence imaging of beta-amyloid, blood vessels (CD31), and microglia (Iba1) in 8-month-old mouse brains, appears sound. Quantitative analysis of vessel density, diameter, signal intensity, and plaque-vessel colocalization using NIH Fiji software, complemented by t-tests, allowed for precise comparisons. While no statistically significant differences were found in vessel density or CD31 intensity, the study revealed crucial findings: a significant decrease in vessel diameter and a substantial increase in plaque-vessel colocalization in the APOE4: APP-SAA cohort. Furthermore, a qualitative assessment pointed to elevated microglial activation, indicative of neuroinflammation, in the APOE4 samples. The observed pathology, encompassing increased neuroinflammation, decreased vessel diameter, and heightened amyloid-beta localization to cerebral small vessels in the APOE4 model, provides a compelling mechanistic framework. This suggests that APOE4 allele-driven vascular alterations could indeed predispose individuals to increased pathological side effects, such as ARIA, when amyloid plaques are targeted for removal. The study's conclusions are well-supported by the quantitative data presented and effectively underscore the critical role of APOE genotype in cerebrovascular health in AD. The recommendation for future studies exploring vascular changes across ages and the model's response to monoclonal antibody therapy is appropriate and promises to further elucidate these important clinical observations.

Full Text

Comments

You need to be logged in to post a comment.